We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HMY:NYSEHarmony Gold Mining Company Limited Analysis

Data as of 2026-06-17 - not real-time

$17.20

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Harmony Gold (HMY) trades at $17.20, comfortably above its 20‑day SMA (≈$16.86) but still below the 200‑day SMA (≈$18.20), indicating a neutral long‑term trend with short‑term bullish bias as the MACD histogram turns positive. The stock offers an estimated 34% upside versus a DCF‑derived fair value and trades at a forward PE of ~5x versus a trailing PE of ~11x, suggesting significant undervaluation relative to earnings. Fundamentally, the company delivers strong profitability – ROE of ~33% and operating margin above 33% – and maintains a modest dividend yield of 2.3% with a low payout ratio (~14%), supporting dividend sustainability. However, the business faces heightened cost pressure (all‑in sustaining costs up 25% YoY) and a high debt‑to‑equity ratio (~25x), while operating in a volatile sector (30‑day volatility ~78%) and a high‑beta environment (beta >2), which amplifies market swings.
Material news points to a strategic shift toward a gold‑copper hybrid model, with the Eva Copper project slated to reshape the revenue mix by 2028, potentially offsetting gold‑price cyclicality but also introducing execution risk in the medium term.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance with bullish MACD signal
  • Elevated cost base and recent production decline
  • Attractive dividend yield with low payout

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Projected 34% upside to fair value
  • Revenue growth of ~20% and diversification into copper
  • Strong cash generation covering debt obligations

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • High ROE and operating margins indicating durable profitability
  • Copper project expected to rebalance revenue mix by 2028
  • Sustainable dividend and low payout ratio supporting shareholder returns

Key Metrics & Analysis

Financial Health

Revenue Growth19.50%
Profit Margin20.05%
P/E Ratio10.8
ROE33.49%
ROA17.30%
Debt/Equity25.47
P/B Ratio3.4
Op. Cash Flow$26.3B
Free Cash Flow$15.1B

Technical Analysis

TrendNeutral
RSI53.0
Support$14.33
Resistance$18.64
MA 20$16.86
MA 50$16.84
MA 200$18.20
MACDBullish
VolumeStable
Fear & Greed Index88.66

Valuation

Fair Value$694.07
Target Price$23.01
Upside/Downside33.83%
GradeUndervalued
TypeBlend
Dividend Yield2.29%

Risk Assessment

Beta2.04
Volatility77.84%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.